← Back to Search


HDR Brachytherapy for Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by CSSS de Gatineau
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gleason Score 6 or 7
Biopsy proven Adenocarcinoma of the Prostate
Must not have
IPSS score 19 or higher with alpha-blockers
Past radiation therapy to the pelvis
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks, 2 years and 5 years post treatment
Awards & highlights


This trial will test how effective and safe high-dose rate brachytherapy is for treating low- and intermediate-risk prostate cancer.

Who is the study for?
This trial is for men with prostate cancer that's not too advanced. Specifically, it's for those who've had a biopsy confirming Adenocarcinoma of the Prostate at an early stage (T1c, T2a or T2b), have a PSA level under 20 ng/ml, and a Gleason Score of 6 or 7.Check my eligibility
What is being tested?
The study is testing if High-dose rate (HDR) brachytherapy alone can be effective in treating low to intermediate risk prostate cancer. HDR brachytherapy involves placing high-energy radiation sources inside the prostate to kill cancer cells.See study design
What are the potential side effects?
Possible side effects from HDR brachytherapy may include discomfort during treatment, urinary issues like frequency or urgency, bowel changes, erectile dysfunction, and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My prostate cancer has a Gleason score of 6 or 7.
My prostate cancer is confirmed by a biopsy.
My breast cancer is in an early stage, but not the smallest size.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
My IPSS score is 19 or higher, and I am taking alpha-blockers.
I have had radiation therapy to my pelvic area.
I am under 18 years old.
My cancer is at a stage where it has grown outside the organ it started in.
My cancer has spread to other parts of my body.
My prostate cancer is aggressive (Gleason score 8+).
I have a history of collagen vascular disease.
I have a history of inflammatory bowel disease.
My cancer has spread to nearby lymph nodes.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks, 2 years and 5 years post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks, 2 years and 5 years post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Disease-free survival
Secondary outcome measures
Genito-urinary (GU) toxicity
Other outcome measures
Gastro-Intestinal (GI) Toxicity
Overall survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: HDR brachytherapy monotherapyExperimental Treatment1 Intervention
Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for prostate cancer include surgery, radiation therapy, hormone therapy, and chemotherapy. Surgery involves the physical removal of the prostate gland, aiming to eliminate cancerous cells. Radiation therapy, such as High-dose rate (HDR) brachytherapy, delivers high doses of radiation directly to cancer cells, causing DNA damage that leads to cell death. Hormone therapy reduces levels of male hormones that can promote cancer growth, while chemotherapy uses drugs to kill rapidly dividing cancer cells. Understanding these mechanisms is crucial for patients as it helps them make informed decisions about their treatment options, manage expectations, and understand potential side effects. Specifically, HDR brachytherapy's targeted approach can minimize damage to surrounding healthy tissues, offering a potentially effective treatment with fewer side effects.
Surgery or radiation: what is the optimal management for locally advanced prostate cancer?

Find a Location

Who is running the clinical trial?

CSSS de GatineauLead Sponsor
1 Previous Clinical Trials
200 Total Patients Enrolled
~7 spots leftby Mar 2026